semaglutide and inflammatory bowel disease Semaglutide-Associated Ischemic Colitis in a Patient Without Traditional Risk Factors: A Case Report ❇️ Inflammatory Bowel Disease (IBD):

Expert guidance from Murphy, TX.

Conclusions/interpretation Progression to diabetes explained less than one-quarter of the risks of clinical outcomes associated with prediabetes

GLP-1glucagon-like peptide 1GLP-1Gila monsterExendin-4GLP-1OzempicWegovyMounjaroGLP-1

Divergence across payer type matters: Commercial patients adopt GLP1s earlier and often remain on monotherapy, while Medicare patients face stricter controls and higher comorbidity burdens

Factors such as side effects, high out-of-pocket costs, injection fatigue and stigma around obesity treatment drive troves of patients some studies estimate roughly half or more to stop GLP-1s within a year and risk regaining the weight they lost